Buprenorphine sublingual- iX Biopharma

Drug Profile

Buprenorphine sublingual- iX Biopharma

Alternative Names: BnoX; Buprenorphine sublingual

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator iX Biopharma
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 14 Feb 2017 Chemical structure information added
  • 03 Jan 2017 iX Biopharma plans a clinical study for Pain in Australia(ACTRN12617000002381)
  • 01 Aug 2016 Preclinical trials in Pain in Australia (Sublingual) before August 2016 (iX Biopharma pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top